Arno Therapeutics, Inc. HomeAbout UsPipelineInvestor RelationsContact Us
Arno Therapeutics is a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs
Arno Theraoeutics, Inc.
Recent Press Releases In the news Contact

September 1, 2015
Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference more »

August 18, 2015
Arno Therapeutics Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer more »

August 14, 2015
Arno Therapeutics Announces Issuance of First Onapristone Patent more »

June 4, 2015
Arno Therapeutics Announces Issuance of First Onapristone Patent more »

June 3, 2015
Arno Therapeutics Announces Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12 more »

May 28, 2015
Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research more »

May 14, 2015
Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 more »

May 13, 2015
Arno Therapeutics Announces Data Validating Continued Onapristone and Companion Diagnostic Development at ASCO Annual Meeting 2015 more »

May 7, 2015
Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone more »

View all Press Releases

July 16, 2015
ASCO 2015: Efficacy of Onapristone in PR-Expressing Tumors, Alexander Zukiwski, MD watch video »

July 16, 2015
ASCO 2015: Safety and PK Results From an Ongoing Phase I-II Study of ONA in Patients With PR-Expressing Cancers, Paul Cottu, MD, MSc watch video »

July 16, 2015
Arno explores new class of antimicrobial drugs more »

July 7, 2015
ASCO 2015: New data support continued onapristone and CDx development more »

April 8, 2015
Arno Therapeutics Seeks to Inhibit Cancer and Enhance Portfolios: CEO Alexander Zukiwski more »

May 23, 2014
Express Yourself: Arno, University of Minnesota pursue gene expression in hopes of developing a companion diagnostic more »

May 19, 2014
Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases more »

May 9, 2014
Maxim: ARNI - Clinical progress on track; Onapristone in two dose escalation trials; Reiterating Buy and $6 price target more »

January 22, 2014
Maxim: ARNI - Onapristone now in clinical development; Revising estimates; Reiterating Buy and $6 price target more »

July 15, 2013
Orphan-Drug Marketing - Medical Marketing & Media (MM&M) eBook more »

July 8, 2013
APRs in CTCs - Drug Discovery News more »

June 13, 2013
Arno Therapeutics’ strategy is to develop onapristone companion diagnostics for each indication - Biopharm Insight more »

View All News

Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(908) 237-0071 Fax